The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade®
We applied validity diagnostics on a heterogenous, observational setting to answer a specific research question. The results indicated that safety effect estimates from many analyses would be inappropriate to interpret as causal, given the data available and methods employed. Validity diagnostics should always be used to determine if the design and analysis are of sufficient quality to support causal inferences. The clinical implications of our findings on IBD suggests that, if an increased risk exists, it is unlikely to be greater than 40% given the 1.40 upper bound of the pooled HR confidence interval.
Authors
- Robert Suruki
- Guy Cafri (ORCID: https://orcid.org/0000-0002-1743-429X)
- Erica A. Voss (ORCID: https://orcid.org/0000-0002-0651-0613)
- James Weaver (ORCID: https://orcid.org/0000-0003-0755-5191)
- Kathleen Beyrau
- Michelle Nashleanas
Institutions
- Johnson & Johnson (United States) (US)
- Janssen (United States) (US)
Publication Details
- Journal
- BMC Medical Research Methodology
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1186/s12874-024-02428-7
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Johnson and Johnson